ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP87-19 Medical Drug Exclusion Lists Expanded to Include Triluron – Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2661 - 2670 လၢ 3679 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP86-19 Pharmacy Benefit Exclusion for Invermectin Cream 1%
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P23R1-19 Alignment of Start Date for Prior Authorization Requests
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP85-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Sunosi ™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 23, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP82-19 Pharmacy Benefit Update – New Insulin Zero Copay Initiative for Commercial Lines of Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 23, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP83-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Egrifta® (tesamorelin)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 23, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P76-19 CMS Changing Payment Classification System for Home Health Effective January 1, 2020
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P85-19 New Colonoscopy Reimbursement Policy for Commercial Lines of Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2019 October Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP17-19 Hearing Aid Coverage for Medicare Advantage and Platinum Blue Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 27, 2019